



ASX and Media Release

Viralytics receives \$1.9 million R&D Tax Incentive

23 October 2013, Sydney, Australia: Viralytics Limited (ASX:VLA, OTCQX:VRACY) has received \$1.9 million from the Australian Taxation Office under the Research and Development Tax Incentive relating to the financial year to 30 June 2013.

This is consistent with the amount estimated and published in the company's 2013 Annual Report.

These funds will be applied to the CAVATAK™ clinical programme to further advance the Phase 2 CALM study in the US in late stage melanoma patients, and to initiate the Phase 1/2 STORM solid tumour patients' study in the United Kingdom this year.

Enquiries:

Dr Malcolm McColl
Chief Executive Officer
02 9988 4000

Mr Rudi Michelson
Monsoon Communications
03 9620 3333

About Viralytics Ltd:

Viralytics is developing oncolytic virotherapy treatments for a range of cancers. Viralytics' lead product, CAVATAK™, is a proprietary formulation of the common cold Coxsackievirus Type A21 (CVA21). CVA21 binds to specific 'receptor' proteins highly expressed on multiple cancer types including, but not limited to: melanoma; prostate, lung, breast and bladder cancers; and multiple myeloma. CAVATAK™ acts to kill both local and metastatic cancer cells, by direct cytolysis and a possible immune response. The preferential targeting of cancer rather than healthy cells provides the potential for low toxicity in the patient. The company is actively enrolling a phase 2 clinical trial, of intratumourally administered CAVATAK™ in the treatment of Late stage Melanoma (the CALM study), at multiple prestigious cancer clinics in the US. The company announced on September 18, 2013 that the primary endpoint in the study had been achieved. Viralytics plans to commence a Phase 1/2 trial of CAVATAK™ being delivered systemically (intravenously). This trial referred to as the STORM (Systemic Treatment Of Resistant Malignancies) study will be undertaken in patients with melanoma, prostate, lung or metastatic bladder cancers. The second stage of the STORM trial will include combination treatments with existing chemotherapies in one of the above cancer types. Viralytics has received regulatory approval from the UK Medicines and Healthcare products Regulatory Agency and will commence the STORM trial at three prominent UK sites in 2013.

Based in Sydney Australia, the company is listed on the Australian Securities Exchange (ASX: VLA) while Viralytics' ADRs also trade under VRACY on the US OTCQX International market.

For personal use only